Search
Brexpiprazole
go.drugbank.com/drugs/DB09128ApprovedInvestigational[A182186, A38385, A259661] Brexpiprazole was first approved by the FDA on July 10, 2015. … Compared to aripiprazole, brexpiprazole has less potential for partial agonist-mediated adverse effects such as extrapyramidal symptoms, which is attributed to lower intrinsic activity at the D2 receptor
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeVorasidenib
go.drugbank.com/drugs/DB17097ApprovedInvestigational[A264209] Vorasidenib was first approved by the FDA on August 6, 2024, for the treatment of Grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation.[L51144] … [A264209] It works by suppressing the levels of D-2-hydroxyglutarate (2-HG), an oncometabolite produced by mutant IDH1 and IDH2 isoforms.
Synonyms: 1,3,5-triazine-2,4-diamine, 6-(6-chloro-2-pyridinyl)-n2,n4-bis((1r)-2,2,2-trifluoro-1-methylethyl)-Bethanechol
go.drugbank.com/drugs/DB01019ApprovedAn advantage of bethanechol is that in contrast to acetylcholine, bethanechol is not degraded by cholinesterase allowing its effects to be longer-lasting.[L32539] … [A232905,L32539] For example, bethanechol is readily used to treat postoperative or postpartum urinary retention.
Synonyms: 2-(carbamoyloxy)-N,N,N-trimethylpropan-1-aminiumSiltuximab
go.drugbank.com/drugs/DB09036ApprovedInvestigationalSiltuximab prevents the binding of IL-6 to soluble and membrane-bound IL-6 receptors by forming high affinity complexes with human interleukin-6 (IL-6). … Siltuximab is a chimeric (human-mouse) monoclonal immunoglobulin G1-kappa antibody produced in a Chinese hamster ovary (CHO) cell line by recombinant DNA technology.
Arsenic trioxide
go.drugbank.com/drugs/DB01169ApprovedInvestigationalArsenic trioxide is a chemotherapeutic agent of idiopathic function used to treat leukemia that is unresponsive to first line agents. … It is suspected that arsenic trisulfide induces cancer cells to undergo apoptosis.
Bulevirtide
go.drugbank.com/drugs/DB15248ApprovedInvestigational[A226305] Bulevirtide, also known as Hepcludex, is a first-in-class entry inhibitor for the treatment of chronic Hepatitis D infection developed by MYR Pharmaceuticals, now part of Gilead. … It was first approved for use in the EU on May 28, 2020; bulevirtide has been granted PRIME scheme eligibility and Orphan Drug Designation by the European Medicines Agency.
Bromotheophylline
go.drugbank.com/drugs/DB14018Approved[L1082] It is also approved by Health Canada to be used alone or in combination with [DB00316] in OTC products.[L1113] … [A33018] Bromotheophylline is categorized on the FDA as a drug substance with an inactive state since March, 1980.
Vigabatrin
go.drugbank.com/drugs/DB01080ApprovedInvestigational[A202124] Its use is now generally reserved for patients who have failed alternative therapies, and its US approval by the FDA in 2009 mandated the creation of a drug registry to monitor patients for visual
Tiratricol
go.drugbank.com/drugs/DB03604ApprovedInvestigationalby chronic tissue thyrotoxicosis and abnormal neuronal development due to the impaired thyroid hormone uptake in the brain. … [L53383] It was first approved by the EMA on February 12, 2025 for the treatment of peripheral thyrotoxicosis in patients with monocarboxylate transporter 8 (MCT8) deficiency,[A274038] a disorder characterized
Categories: Agents used to treat hypothyroidismEnzalutamide
go.drugbank.com/drugs/DB08899ApprovedInvestigational[A252667] Second-generation such as enzalutamide is more efficacious due to a higher affinity to AR and no partial agonist activity compared to bicalutamide. … Compared to the average time of 10 to 15 years for a drug to go from pre-clinical to clinical studies, enzalutamide was developed relatively rapidly.[A252667]
Categories: Antiandrogens, non-steroidal